Qinghuang powder components tested on senescent bone marrow stem cells in MDS
In an in vitro co-culture of patient-derived bone marrow mesenchymal stem cells and an MDS cell line, the Qinghuang powder components As2S2 and indirubin were reported to reduce senescence markers and partially improve metabolic abnormalities. This is laboratory work, not evidence of benefit in people. [1]
Automatic summary · not editorially reviewed
The key findings
Qinghuang powder contains Indigo naturalis, a source of indirubin, and Realgar, which contains As2S2. [1]
In vitro, patient-derived BMMSCs co-cultured with the MDS cell line SKM-1 were treated with As2S2 and indirubin, and senescence and metabolic markers were measured. [1]
The authors propose that QHP components alleviated BMMSC senescence and partially ameliorated metabolic abnormalities, possibly via glycolysis and the AMPK/EZH2 axis. [1]
The source at a glance
- Study type / format
- In vitro laboratory study (abstract)
- Population / context
- Patient-derived bone marrow mesenchymal stem cells co-cultured with the MDS cell line SKM-1, compared with healthy controls
- Summary based on
- Study abstract
- Original publication
- August 24, 2026
MDS stromal niche as the study target
The abstract states that myelodysplastic syndromes (MDS) are haematological malignancies and that the traditional Chinese medicine preparation Qinghuang powder (QHP) has been reported to relieve MDS symptoms and delay progression. QHP contains Indigo naturalis, a source of indirubin, and Realgar, which contains As2S2. The authors say the mechanisms, especially protection and remodelling of the senescent and metabolically impaired bone marrow stromal niche such as bone marrow mesenchymal stem cells (BMMSCs), were not fully clarified. The study therefore shifts focus from malignant blood-forming clones to this stromal microenvironment and asks how As2S2 and indirubin might act on MDS-associated BMMSC senescence and metabolic imbalance.
Supporting source [1]
Co-culture measurements of senescence and metabolism
The abstract describes an in vitro co-culture of patient-derived BMMSCs with the MDS cell line SKM-1, treated with As2S2 and indirubin. Senescence, the senescence-associated secretory phenotype (SASP) and metabolic profiles were assessed with SA-β-Gal staining, Seahorse metabolic assays, ELISA, flow cytometry, qPCR and Western blotting. Compared with healthy controls, MDS-BMMSCs showed impaired proliferation and significantly elevated SA-β-Gal positivity. Co-culture with SKM-1 cells reportedly worsened this senescent state and led to substantial secretion of pro-inflammatory SASP factors such as IL-6. The abstract text is truncated, so full numerical results and statistics are not available here.
Supporting source [1]
Proposed mechanism and limits of the evidence
The conclusion proposes a microenvironment-targeted paradigm for QHP. It states that MDS tumour cells induced senescence and metabolic fragility in BMMSCs with inflammatory secretion, and that the QHP components alleviated BMMSC senescence and partially ameliorated metabolic abnormalities. These remodelling effects may involve selective curtailment of abnormal glycolysis and may be involved in or associated with regulation of the AMPK/EZH2 signalling axis. The authors frame this as potential for targeting stromal metabolic vulnerabilities with traditional Chinese medicine. All of this comes from an in vitro system using a cell line and patient-derived cells; the abstract reports no human trial, no clinical outcomes and no confirmed causal mechanism.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is an in vitro co-culture study using a cell line and patient-derived cells, with no human trial or clinical outcomes reported. The abstract text is truncated, so some results and statistics are missing. Proposed mechanisms are not established causes.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Jiang P, Sun D, Zhang Y, Wang D, He J, Tang X. · europepmc.org · August 24, 2026